

Form PTO-1449

Docket Number 304142000321

Application Number 08/766,350

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Malaya CHATTERJEE et al

Filing Date December 13, 1996

Group Art Unit 1642

Mailing Date June 30, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
SR	1.	08/14/2001	6,274,143	Chatterjee et al.	—	—	—

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
SR	2.	08/08/1991	WO 91/11508	WIPO	/	/	/
↓	3.	05/29/1992	WO 92/08495	WIPO <i>DUPLICATE</i>	/	/	/
↓	4.	05/23/2002	WO 02/40501	WIPO	/	/	/

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
SR	5.	Amalfitano, A. et al. (2002). "Separating Fact From Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy," <i>Current Gene Therapy</i> 2(2):111-133.
	6.	Benvenuti, F. et al. (2000). "Anti-idiotypic DNA Vaccines for Lymphoma Immunotherapy Require the Presence of Both Variable Region Genes for Tumor Protection," <i>Gene Therapy</i> 7(7):605-611.
	7.	Benvenuti, F. et al. (2001). "Anti-idiotypic Antibodies Induced by Genetic Immunisation are Directed Exclusively Against Combined VL/VH Determinants," <i>Gene Therapy</i> 8(20):1555-1561.
	8.	Berzoksky, J.A. and Berkower, I.I. (1993). "Immunogenicity and Antigen Structure," Chapter 8 In <i>Fundamental Immunology</i> , William E. Paul ed., Raven Press NY, page 242.
	9.	Bodey, B. et al. (2000). "Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy," <i>Anticancer Research</i> 20:2665-2676.
	10.	Browning, J. L. et al. (1993). "Lymphotoxin β , a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface," <i>Cell</i> (72):847-856.
	11.	Darsley, M. J. et al. (1985). "Nucleotide Sequences of Five Anti-Lysozyme Monoclonal Antibodies," <i>EMBO J.</i> 4(2):393-398.
↓	12.	De Waele, P. et al. (1988). "Expression in Non-Lymphoid Cells of Mouse Recombinant Immunoglobulin Directed Against The Tumour Marker Human Placental Alkaline Phosphatase," <i>Eur. J. Biochem.</i> 176:287-295.

EXAMINER:

DATE CONSIDERED:

12/15/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 304142000321

Application Number 08/766,350

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

Applicant

Malaya CHATTERJEE et al

Filing Date December 13, 1996

Group Art Unit 1642

Mailing Date June 30, 2004

(Use several sheets if necessary)

13. Gavilondo, J.V. et al. (2000). "Antibody Engineering at the Millennium," *Biotechniques* 29(1): 128-145.
14. Houdebine, L-M. (1994). "Production of Pharmaceutical Proteins From Transgenic Animals," *Journal of Biotechnology* 34:269-287.
15. Kavalier, J. et al. (1990). "A Set of Closely Related Antibodies Dominates The Primary Antibody Response To The Antigenic Site CB of The A/PR/8/34 Influenza Virus Hemagglutinin," *J. Immun.* 145(7):2312-2321.
16. Kennedy, R. C. et al. (1985). "Vaccines Utilizing Internal Image Anti-Idiotypic Antibodies that Mimic Antigens of Infectious Organisms," *Biotechniques* 3(5):404-410.
17. Liu, A. Y. et al. (1987). "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 With Potent Fc-Dependent Biologic Activity," *J. Immunol.* 139(10):3521-3526.
18. Mo, J. A. et al. (1993). "Variable Region Gene Selection of Immunoglobulin G-Expressing B Cells With Specificity For a Defined Epitope On Type II Collagen," *Eur. J. Immunol.* 23:2503-2510.
19. Pandha, H. S et al. (2000). "Oncological Applications of Gene Therapy," *Current Opinion in Investigation Drugs* 1(1):122-134.
20. Pandya, K. J. et al. (1985). "A Retrospective Study of Earliest Indicators of Recurrence in Patients On Eastern Cooperative Oncology Group Adjuvant Chemotherapy Trials For Breast Cancer. A Preliminary Report," *Cancer* 55(1):202-205.
21. Patterson, A. P. (2003). "Principles Investigators for Human Gene Transfer Trials Employing Retroviral Vectors. Notification of a Serious Adverse Event. Department of Health and Human Service, pp.1-3.
22. Reeck et al. (1987). "Homology," ~~Protein and Nucleic Acids: A Terminology Muddle and Way out of It,~~ *Cell* 50(5):667.
23. Schouten, D. et al. (1993). "Development of Lipoprotein-like Lipid Particles for Drug Targeting Neo-High Density Lipoproteins," *Molecular Pharmacology* 44(2):486-492.
24. Seidman, J. G. et al. (1979). "A κ -Immunoglobulin Gene is Formed by Site-Specific Recombination without Further Somatic Mutation," *Nature* 280(5721):370-375.
25. Shlomchik, M. et al. (1990). "Anti-DNA Antibodies from Autoimmune Mice Arise by Clonal Expansion and Somatic Mutation," *J. Exp. Med.* 171(1):265-297.
26. Stevenson, F. K. et al. (1995). "Idiotypic DNA Vaccines Against B-Cell Lymphoma," *Immunological Reviews* 145:211-228.
27. Zeytin, H. E. et al. (2000). "Construction and Characterization of DNA Vaccines Encoding the Single-Chain Variable Fragment of the Anti-Idiotypic Antibody 1A7 Mimicking the Tumor-Associated Antigen Disialoganglioside GD2," *Cancer Gene Ther.* 7(11):1426-1436.
28. Verma, I. M. et al. (1997). "Gene Therapy-Promises, Problems and Prospects," *Nature* 389:239-242.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

pa- 746601